LC

Litmore Capital

Description

Litmore Capital

Investor Profile

Litmore Capital has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (50%)
  • Series Unknown (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Precision Medicine
  • Health Diagnostics
  • Neuroscience
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Litmore Capital frequently co-invest with?

Connecticut Innovations
North America, Connecticut, United States, Rocky Hill
Co-Investments: 2
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
Aperture Venture Partners
North America, New York, United States, New York
Co-Investments: 2
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 2
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 2
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 2
Venrock
North America, California, United States, Palo Alto
Co-Investments: 2
Aisling Capital
North America, New York, United States, New York
Co-Investments: 2

Which angels does Litmore Capital often collaborate with?

CI
North America, New York, United States, New York
Shared Deals: 1
Shared Deals: 2
GB
Europe, England, United Kingdom, London
Shared Deals: 2

What are some of recent deals done by Litmore Capital?

Bristol-Myers Squibb

New York, New York, United States

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Post Ipo EquityFeb 21, 2017
Amount Raised: $80,000,000
Biohaven Pharmaceutical

New Haven, Connecticut, United States

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

BiotechnologyHealth CareHealth DiagnosticsNeurosciencePharmaceutical
Series UnknownNov 1, 2016
Amount Raised: $80,000,000